Medicine guide
Zontivity
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Vorapaxar
- Used in
- Blood, clotting and anaemia
- Made by
- Merck Sharp Dohme Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Zontivityis indicated for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or symptomatic peripheral arterial disease (PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Merck Sharp Dohme Limited |
|---|---|
| Active substance | Vorapaxar |
| Used in | Blood, clotting and anaemia |
| Classification | B01 · Blood, clotting and anaemia |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2015-01-19 |
| Last updated by the regulator | 2017-09-20 |
| EMA product number | EMEA/H/C/002814 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).